Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Management of congenital duodenal obstruction in neonates: a 10-year retrospective cohort study from a National Children's Hospital.

Surgical endoscopy·2026

Same author

Text-Embedding-Assisted Design of Rigid Molecular Cations for Suppressing Ion Migration in Hybrid Single-Crystal X-ray Detectors.

The journal of physical chemistry letters·2026

Same author

Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancer.

Nature immunology·2026

Same author

Identifying mitochondrial genes and potential biological functions in pre-eclampsia: bioinformatics and experimental insights.

Frontiers in genetics·2026

Same author

Structurally diverse clerodane diterpenoids with anti-inflammatory and anti-diabetic effects from Tinospora crispa (L.) Hook.f. & Thomson.

Phytochemistry·2026

Same author

Study on the evaluation of left atrial structure and function in patients with H-type hypertension using 4D automated left atrial quantitative.

BMC cardiovascular disorders·2026

Same journal

Preclinical evaluation of novel FGFR2-targeting peptide probes for PET imaging and intraoperative navigation in gastric Cancer.

Bioorganic chemistry·2026

Same journal

New functionalized silica nanoparticles (SiNPs) as a potential daunorubicin delivery platform: an in vitro proof-of-concept evaluation.

Bioorganic chemistry·2026

Same journal

Aloin suppresses cancer cell growth via autophagy-promoted NEDD8 de-NEDDylation to target GPX4 for ferroptosis induction.

Bioorganic chemistry·2026

Same journal

Design, synthesis, and biological evaluation of novel selenium-matrine hybrid compounds as topo I -targeted anticancer agents.

Bioorganic chemistry·2026

Same journal

Discovery of novel tyrosinase-inhibitory peptides FW and LAW from bullfrog (Lithobates catesbeianus) muscle protein: In silico screening, inhibition kinetics, gastrointestinal stability, and anti-melanogenic efficacy in zebrafish.

Bioorganic chemistry·2026

Same journal

Tumor-targeted activatable molecular agent for synergistic chemo-photodynamic therapy.

Bioorganic chemistry·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 21, 2026

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

Recent advances in HDAC-based multi-target inhibitors.

Yinuo Fu¹, Chenyang Yu¹, Yuxi Guo¹

¹College of Pharmacy, South-Central Minzu University, Wuhan, Hubei 430074, China.

Bioorganic Chemistry

|June 19, 2026

Summary

This summary is machine-generated.

Histone deacetylase (HDAC) inhibitors show promise for solid tumors. Multi-target HDAC inhibitors enhance efficacy and reduce resistance, offering new therapeutic avenues for various diseases.

Keywords:

Anticancer agent Dual-target inhibitor Epigenetic regulation Histone deacetylase

More Related Videos

Assays for Validating Histone Acetyltransferase Inhibitors

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique

Published on: January 14, 2016

Related Experiment Videos

Last Updated: Jun 21, 2026

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

Assays for Validating Histone Acetyltransferase Inhibitors

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique

Published on: January 14, 2016

Area of Science:

Medicinal Chemistry
Pharmacology
Oncology

Background:

Histone deacetylase (HDAC) inhibitors are approved for hematologic malignancies.
Their use in solid tumors is limited by efficacy, resistance, and toxicity.
Multi-target inhibitors present a strategy to overcome these limitations.

Purpose of the Study:

To review recent advancements in HDAC-based multi-target compounds.
To emphasize target selection, molecular design, and structure-activity relationships.
To highlight biological activities and therapeutic potential.

Main Methods:

Literature review of recent studies on HDAC-based multi-target compounds.
Analysis of target selection and molecular design strategies.
Evaluation of structure-activity relationships and biological data.

Main Results:

Dual-target HDAC inhibitors demonstrate enhanced synergistic effects.
These compounds show potential in overcoming drug resistance and reducing toxicity.
Successful examples of multi-target HDAC inhibitors are discussed.

Conclusions:

HDAC-based multi-target compounds offer a promising approach for solid tumor treatment.
Further research into molecular design and biological evaluation is warranted.
These inhibitors hold potential for treating tumors, neurological, and inflammatory diseases.